Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine  

作　　者：Chang-quan Ling Jia Fan Hong-sheng Lin Feng Shen Zhen-ye Xu Li-zhu Lin Shu-kui Qin Wei-ping Zhou Xiao-feng Zhai Bai Li Qing-hui Zhou 

机构地区：[1]Department of Integrative Oncology,Changhai Hospital of Traditional Chinese Medicine,Second Military Medical University,Shanghai 200433,China [2]Department of Liver Surgery and Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China [3]Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China [4]Department of Hepatobiliary Surgery,Eastern Hepatabiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China [5]Department of Oncology,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China [6]Department of Oncology,First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,China [7]Cancer Center of Bayi Hospital,Nanjing University of Chinese Medicine,210002,China [8]Department of Rehabilitative Medicine,Changhai Hospital of Traditional Chinese Medicine,Second Military Medical University,Shanghai 200433,China [9]Department of Acupuncture-Moxihustion and Tuina,Changhai Hospital of Traditional Chinese Medicine,Second Military Medical University,Shanghai 200433,China

出　　处：《Journal of Integrative Medicine》2018年第4期236-248,共13页结合医学学报（英文版）

基　　金：funded by the Shanghai Municipal Commission of Health and Family Planning(Grant Number ZY3-LCPT-2-1004);National Natural Science Foundation of China(Grant Number81503459);E-Institutes of Shanghai Municipal Education Commission(Grant Number E03008)

摘　　要：Traditional Chinese medicine （TCM） is an important part of the treatment of primary liver cancer （PLC） in China; however, the current instructions for the integrative use of traditional Chinese and Western medicine for PLC are mostly based on expert opinion. There is no evidence-based guideline for clinical prac-tice in this field. Therefore, the Shanghai Association of Chinese Integrative Medicine has established a multidisciplinary working group to develop this guideline, which focuses on the most important questions about the use of TCM during PLC treatment. This guideline was developed following the method- ological process recommended by the World Health Organization Handbook for Guideline Development. Two rounds of questionnaire survey were performed to identify clinical questions; published evidence was searched; the Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the body of evidence; and recommendations were formulated by combining the quality of evidence, patient preferences and values, and other risk factors. The guideline was written based on the Reporting Items for Practice Guidelines in Healthcare tool. This guideline contains 10 recommendations related to 8 questions, including recommendations for early treatment by TCM after surgery, TCM combined with transcatheter arterial chemoembolization for advanced PLC, TCM drugs for external use, and acupuncture and moxibustion therapy.Traditional Chinese medicine （TCM） is an important part of the treatment of primary liver cancer （PLC） in China; however, the current instructions for the integrative use of traditional Chinese and Western medicine for PLC are mostly based on expert opinion. There is no evidence-based guideline for clinical prac-tice in this field. Therefore, the Shanghai Association of Chinese Integrative Medicine has established a multidisciplinary working group to develop this guideline, which focuses on the most important questions about the use of TCM during PLC treatment. This guideline was developed following the method- ological process recommended by the World Health Organization Handbook for Guideline Development. Two rounds of questionnaire survey were performed to identify clinical questions; published evidence was searched; the Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the body of evidence; and recommendations were formulated by combining the quality of evidence, patient preferences and values, and other risk factors. The guideline was written based on the Reporting Items for Practice Guidelines in Healthcare tool. This guideline contains 10 recommendations related to 8 questions, including recommendations for early treatment by TCM after surgery, TCM combined with transcatheter arterial chemoembolization for advanced PLC, TCM drugs for external use, and acupuncture and moxibustion therapy.

关 键 词：Primary liver cancerClinical practice guidelines TRADITIONAL Chinese medicineIntegrative medicine 

分 类 号：R735.7[医药卫生—肿瘤]